Technology

Reimagining  in vivo cell therapy

CPTx is pioneering immune-silent single-stranded DNA (ssDNA) vectors as a new foundation for in vivo CAR T therapies. Our ssDNA + LNP platform is redosable, tunable, and durable, a clear contrast to viral & nonviral vectors that permanently integrate and to mRNA approaches that fade too quickly for oncology.

Our lead dual CAR program targets CD19/CD20 to treat relapsed/refractory diffuse large B-cell lymphoma, and we see broad potential for our in vivo CAR T platform to extend to additional hematologic malignancies, solid tumors, and—beyond oncology—autoimmune diseases.

Non-viral, durable, redosable.

Traditional viral delivery methods and mRNA face well-known limitations, including the risk of immune activation, restrictions on payload size, lack of tissue specificity, and significant manufacturing complexity. Our in vivo CAR-T therapies avoid these limitations.

Built with ssDNA + non viral LNPs, our in vivo CAR-T therapies offer:

Immune-silent,  repeatable dosing

Precise tissue and  cell targeting

Scalable, modular manufacturing

Tunable and  durable effect

Beyond CAR-T

A versatile
platform

While we are currently focused on oncology, our platform can be leveraged for a variety of in vivo gene therapies, offering modular control over:

Payload mRNA & DNA for gene expression
Targeting ligands & receptor effectors
Combinatorial payloads for immune modulation

What if gene delivery did not require an external carrier?

Using computational design, our novel targeting gene carriers are constructed with single-stranded DNA that folds around its main cargo, the therapeutic single-stranded DNA it is delivering to target cells. These non-viral, non-LNP carriers are non-toxic, non-immunogenic, and non-inflammatory. They can be constructed to encode for virtually any gene of interest and for precise in vivo tissue and cell targeting. Importantly, using proprietary process innovations, we can manufacture the gene carriers in a scalable fashion.

Our novel gene carrier unlocks an entirely new approach to in vivo gene delivery, overcoming critical limitation of existing viral and non-viral gene delivery technologies such as immunogenicity, inflammation and reactogenicity, poor targetability, and tedious manufacturing which have held back the genetic medicines field from bringing critical therapies to patients.

Our DNA self carrier (DSC) technology is part of our broader platform vision and a component for both internal and external partner-facing projects.

Built for a growing network of partners

Through gxstrands, our internal CDMO, we manufacture long, high-sequence-fidelity ssDNA constructs at research and clinical scale, serving CPTx and a growing network of partners.

Vector design and ssDNA manufacturing that set us apart

Pharmaceutical and biotech companies come to us not only for product innovation — but also for our unique ability to build what others can’t. We welcome collaborations across research, clinical development, and advanced DNA manufacturing.

Let’s build the future of CAR-T together.

We invite you to explore how our precision DNA therapies can accelerate your breakthroughs.

Explore Partnerships